Xenon Pharmaceuticals
XENE
80 hedge funds and large institutions have $308M invested in Xenon Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
1% more funds holding
Funds holding: 79 → 80 (+1)
0.16% less ownership
Funds ownership: 79.95% → 79.79% (-0.16%)
12% less capital invested
Capital invested by funds: $351M → $308M (-$42.7M)
41% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 27
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.01M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.93M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$561K |
| 5 |
Goldman Sachs
New York
|
+$385K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.56M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.5M |
| 3 |
Renaissance Technologies
New York
|
-$1.55M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.48M |
| 5 |
JP Morgan Chase
New York
|
-$1.21M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Citigroup
New York
| $3K | -$54.7K | -4,647 | -94% |
|
77
Millennium Management
New York
| $1.32K | -$578K | -49,151 | -29% |
|
78
BNP Paribas Financial Markets
Paris,
France
| $1.05K | +$1.12K | +95 | New |
|
|
79
JP Morgan Chase
New York
| – | -$1.21M | -96,372 | Closed |
|
80
Squarepoint
New York
| – | -$305K | -24,321 | Closed |
|
|
ECM
81
ExodusPoint Capital Management
New York
| – | -$249K | -19,888 | Closed |
|
|
DWA
82
Dorsey Wright & Associates
Pasadena,
California
| – | -$9K | -674 | Closed |
|
83
Simplex Trading
Chicago,
Illinois
| – | -$1K | -126 | Closed |
|
|
CHA
84
Carmichael Hill & Associates
Gaithersburg,
Maryland
| – | +$294 | +25 | New |
|
XENE Hedge Fund Activity: Q3 2020 in Review
80 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2020, worth a combined $308M — down 12% from $351M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 16 added to existing stakes and 27 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $5.01M. The largest seller was Acuta Capital Partners, cutting an estimated $2.56M.
- 80 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2020, up from 79 in Q2 2020.
- Funds reported $308M of Xenon Pharmaceuticals stock for Q3 2020, down 12% quarter-over-quarter.
- 6 funds opened new Xenon Pharmaceuticals positions in Q3 2020 and 5 closed out, a net change of +1 holder.
- The largest Xenon Pharmaceuticals buyer in Q3 2020 was Fidelity Investments, an estimated $5.01M added.
- The largest Xenon Pharmaceuticals seller in Q3 2020 was Acuta Capital Partners, an estimated $2.56M sold.
Based on aggregated 13F filings for Q3 2020.